by Columbia University A peptide that stimulates receptors in neurons reduced the amount of toxic tau proteins present. Tau proteins are labeled yellow. Left image shows untreated neurons; right image shows neurons treated with the peptide. Credit: Natura Myeku A new idea for treating Alzheimer’s disease could eradicate the toxic proteins most closely linked to cognitive decline in...
Cholinesterase inhibitors are a group of drugs recommended for the treatment of Alzheimer’s disease, but their effects on cognition have been debated and few studies have investigated their long-term effects. A new study involving researchers from Karolinska Institutet and published in the journal Neurology shows persisting cognitive benefits and reduced mortality for up to five years after...
by Tokyo Medical and Dental University Alzheimer’s remains the leading cause of dementia in Western societies, with some estimates suggesting that as many as 24 million people worldwide are living with the disease. Alzheimer’s is characterized by a progressive decline in cognitive ability that eventually affects even basic functions such as walking and swallowing. The...
Far-infrared free-electron laser is useful in breaking down protein aggregates and has attractive applications in medicine and bio material engineering TOKYO UNIVERSITY OF SCIENCE Amyloid fibrils are a type of self-assembled proteins/peptides that take on a stacked sheet-like formation. Amyloid fibril aggregates are known to be a cause of several diseases–including Alzheimer’s–and therefore, it is...
The U.S. health care system lacks the capacity to rapidly move a treatment for Alzheimer’s disease from approval into wide clinical use, a shortcoming that could leave millions of people without access to transformative care if such a breakthrough occurs, according to a new RAND Corporation study. The primary problem is that there are too few...
